Related Experiment Video

Updated: Aug 11, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

FYN: emerging biological roles and potential therapeutic targets in cancer

SanFei Peng1, Yang Fu2

  • 1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Journal of Translational Medicine
|February 5, 2023
PubMed

Insights

FYN, a Src family kinase, drives tumor growth and metastasis. Targeting FYN offers a promising therapeutic strategy to improve cancer patient prognosis and survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Src family protein kinases (SFKs) are crucial in tumor development, regulating cell adhesion, invasion, proliferation, survival, apoptosis, and angiogenesis.
  • SFKs are frequently overexpressed or hyperactive in tumors, participating in critical tumorigenesis signaling pathways.
  • FYN, an SFK member, is highly expressed in various cancers, promoting growth, metastasis, and drug resistance.

Purpose of the Study:

  • To provide a comprehensive overview of FYN's role in cancer.
  • To detail FYN's structure, expression patterns, upstream regulators, and downstream targets.
  • To elucidate FYN's diverse biological functions in tumor progression.

Main Methods:

  • This review synthesizes existing literature on FYN's involvement in cancer.
  • Information was gathered on FYN's molecular structure and interactions.
  • Data on FYN's expression, regulation, and functional roles in tumorigenesis were analyzed.

Main Results:

  • FYN regulates key cellular processes including growth, apoptosis, and motility.
  • FYN interacts with multiple cancer-related signaling pathways like ERK, COX-2, STAT5, MET, and AKT.
  • FYN's hyperactivity is linked to enhanced tumor growth, metastasis, and drug resistance.

Conclusions:

  • FYN is a significant driver of cancer progression and metastasis.
  • FYN represents an attractive therapeutic target for various cancers.
  • Inhibiting FYN holds potential for improving patient prognosis and survival outcomes.
Keywords:
Biological functionsFYNTargeted therapycancer

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.4K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K